Squarepoint Ops LLC Takes $385,000 Position in ImmunityBio, Inc. (NASDAQ:IBRX)

Squarepoint Ops LLC purchased a new stake in ImmunityBio, Inc. (NASDAQ:IBRX) during the 2nd quarter, according to its most recent Form 13F filing with the SEC. The institutional investor purchased 60,936 shares of the company’s stock, valued at approximately $385,000.

A number of other institutional investors have also recently bought and sold shares of the business. Virtu Financial LLC bought a new position in shares of ImmunityBio in the 4th quarter valued at $304,000. Brookstone Capital Management bought a new position in ImmunityBio in the 1st quarter worth approximately $100,000. Courier Capital LLC lifted its holdings in shares of ImmunityBio by 33.3% in the first quarter. Courier Capital LLC now owns 20,000 shares of the company’s stock worth $107,000 after buying an additional 5,000 shares in the last quarter. China Universal Asset Management Co. Ltd. raised its holdings in shares of ImmunityBio by 66.1% in the 1st quarter. China Universal Asset Management Co. Ltd. now owns 128,321 shares of the company’s stock valued at $689,000 after acquiring an additional 51,086 shares in the last quarter. Finally, Mirae Asset Global Investments Co. Ltd. raised its position in ImmunityBio by 41.9% during the first quarter. Mirae Asset Global Investments Co. Ltd. now owns 59,411 shares of the company’s stock valued at $319,000 after purchasing an additional 17,549 shares in the last quarter. Institutional investors own 8.58% of the company’s stock.

ImmunityBio Stock Performance

NASDAQ IBRX opened at $3.23 on Friday. The company has a market capitalization of $2.23 billion, a price-to-earnings ratio of -2.96 and a beta of 1.02. The stock has a 50-day moving average of $3.81 and a 200 day moving average of $5.48. ImmunityBio, Inc. has a one year low of $1.25 and a one year high of $10.53.

ImmunityBio (NASDAQ:IBRX) last released its earnings results on Monday, August 12th. The company reported ($0.20) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.17) by ($0.03). The company had revenue of $1.05 million for the quarter, compared to the consensus estimate of $2.53 million. On average, equities analysts predict that ImmunityBio, Inc. will post -0.86 earnings per share for the current fiscal year.

Wall Street Analysts Forecast Growth

Separately, Piper Sandler reduced their target price on ImmunityBio from $6.00 to $4.75 and set a “neutral” rating on the stock in a research note on Monday, August 19th.

ImmunityBio Profile

ImmunityBio, Inc, a clinical-stage biotechnology company, engages in developing therapies and vaccines that bolster the natural immune system to defeat cancers and infectious diseases. Its platforms for the development of biologic product candidates include antibody-cytokine fusion proteins; DNA, RNA, and recombinant protein vaccines; and cell therapies.